Cancers,
Journal Year:
2023,
Volume and Issue:
15(16), P. 4143 - 4143
Published: Aug. 17, 2023
In
this
editorial
context,
we
aim
to
leverage
the
potential
of
proteogenomics,
which
integrates
genomic
and
proteomic
data,
discover
novel
biomarkers
that
can
aid
in
diagnosis
management
prostate
cancer.
We
highlight
importance
proteogenomics
for
understanding
functional
consequences
somatic
mutations
cancer
demonstrating
how
proteogenomic
analysis
provide
insights
into
effects
genetic
alterations
on
landscape
identify
therapeutic
targets.
This
article
also
emphasizes
urine
detection
Overall,
our
paper
provides
general
application
identification
International Journal of Molecular Sciences,
Journal Year:
2023,
Volume and Issue:
24(8), P. 7482 - 7482
Published: April 19, 2023
Prostate
cancer
(PCa)
continues
to
rank
as
the
second
leading
cause
of
cancer-related
mortality
in
western
countries,
despite
golden
treatment
using
androgen
deprivation
therapy
(ADT)
or
anti-androgen
therapy.
With
decades
research,
scientists
have
gradually
realized
that
existence
prostate
stem
cells
(PCSCs)
successfully
explains
tumor
recurrence,
metastasis
and
therapeutic
failure
PCa.
Theoretically,
eradication
this
small
population
may
improve
efficacy
current
approaches
prolong
PCa
survival.
However,
several
characteristics
PCSCs
make
their
diminishment
extremely
challenging:
inherent
resistance
chemotherapy
treatment,
over-activation
survival
pathway,
adaptation
micro-environments,
escape
from
immune
attack
being
easier
metastasize.
For
end,
a
better
understanding
PCSC
biology
at
molecular
level
will
definitely
inspire
us
develop
targeted
approaches.
In
review,
we
comprehensively
summarize
signaling
pathways
responsible
for
homeostatic
regulation
discuss
how
eliminate
these
fractional
clinical
practice.
Overall,
study
deeply
pinpoints
provides
some
research
perspectives.
ACS Sensors,
Journal Year:
2025,
Volume and Issue:
unknown
Published: March 4, 2025
Engrailed-2
(EN2)
protein,
a
transcription
factor
in
the
homologous
domain
expressed
prostate
cancer
(PCa)
cells
and
secreted
into
urine,
is
considered
promising
biomarker
for
noninvasive
detection
of
PCa.
EN2
protein
urine
samples
can
be
obtained
by
means,
but
low
concentration
poses
great
challenge
PCa
biomarker.
Herein,
we
develop
solution-gated
graphene
transistor
(SGGT)
biosensor
to
detect
diagnosis.
The
aptamer
probes
are
immobilized
gold
gate
electrode
through
Au-S
bonds.
effect
configurations
on
biosensor's
responses
also
investigated.
It
found
that
SGGT
with
long-chain
stem-like
loop
structure
exhibits
optimal
performance.
limit
biosensors
reach
0.1
fg/mL,
rapid
response
time
19
min
achieved.
high
specificity
protein.
More
importantly,
testing
clinical
indicates
our
sensor
distinguish
patients
from
non-PCa
subjects.
Compared
traditional
hospital
prostate-specific
antigen
tests,
better
accuracy
diagnosis
Biology,
Journal Year:
2025,
Volume and Issue:
14(3), P. 256 - 256
Published: March 4, 2025
Background:
Prostate
cancer
(PCa),
is
the
second
most
prevalent
solid
tumor
among
men
worldwide
(7.3%),
and
leading
non-skin
in
USA
where
it
represents
14.9%
of
all
new
cases
diagnosed
2024.
This
multifactorial
disease
exhibits
substantial
variation
incidence
mortality
across
different
ethnic
groups
geographic
regions.
Although
prostate-specific
antigen
(PSA)
remains
widely
used
as
a
biomarker
for
PCa,
its
limitations
reduce
effectiveness
accurate
detection.
Consequently,
finding
molecules
that
can
either
complement
PSA
other
biomarkers
major
goal
PCa
research.
Methods:
Urine
samples
were
collected
from
healthy
donors
(n
=
5)
patients
with
low-
high-risk
(4
7
subjects,
respectively)
analyzed
using
proteomic
data-derived
systems
biology
approaches.
The
promising
proteins
further
investigated
by
means
Cancer
Genome
Atlas
(TCGA)
database
to
assess
their
associations
clinical
histopathological
characteristics
larger
silico
patient
population.
Results:
By
evaluating
variations
urinary
proteome
mirror
changes
occurring
prostate
tissue,
components
coagulation
cascades
glutathione
metabolism
emerged
hallmarks
patients,
respectively.
Moreover,
our
integrated
approach
highlighted
potential
biomarkers,
including
CPM,
KRT8,
ITIH2,
RCN1.
Conclusions:
good
overlap
results
what
already
reported
literature
supports
findings
perspective
improving
knowledge
on
PCa.
Furthermore,
they
increase
panel
could
enhance
management.
Of
course,
investigations
cohorts
are
required.
Tzu Chi Medical Journal,
Journal Year:
2025,
Volume and Issue:
37(2), P. 117 - 124
Published: April 1, 2025
Urinary
tract
infection
(UTI)
of
the
urinary
bladder
is
a
common
bacterial
that
predominantly
affects
women,
with
many
experiencing
recurrent
episodes.
Recurrent
UTIs
(rUTIs)
are
associated
significant
physical,
psychological,
and
social
difficulties.
Further,
they
closely
related
to
lower
dysfunction
(LUTD).
LUTD
function
structure,
thereby
contributing
urgency,
frequency,
incontinence,
which,
in
turn,
increases
risk
infections
due
impaired
urothelial
defense
mechanisms.
The
current
study
explored
pathophysiology
women
rUTIs.
Potential
treatments
for
rUTIs
include
long-term
prophylactic
antibiotics,
probiotics,
D-mannose,
vaccines,
small
molecule
inhibitors,
stem
cell
therapy.
Moreover,
it
evaluated
use
platelet-rich
plasma
(PRP)
therapy
as
treatment
modality
LUTD.
PRP
has
regenerative
anti-inflammatory
properties.
Hence,
can
be
promising
option
enhancing
barrier
integrity
reducing
recurrence.
Repeated
intravesical
injections
effective
improving
symptoms
decreasing
UTI
recurrences
by
proliferative
ability
urothelium
patients
this
review
examined
potential
predictors
successful
outcomes
such
cytokine
biomarker
levels,
which
provided
insights
into
patient
selection
individualized
strategies.
Identifying
predictive
biomarkers
responsiveness
essential
optimizing
improve
clinical
quality
life
rUTIs,
future
research
should
focus
on
refining
PRP,
exploring
combination
therapies,
validating
biomarkers.
European Urology Oncology,
Journal Year:
2025,
Volume and Issue:
unknown
Published: May 1, 2025
The
interplay
between
prostate
cancer
and
the
tumor
microenvironment
is
well
documented
of
primary
importance
in
disease
evolution.
Herein,
we
investigated
prognostic
value
tissue
urinary
collagen-related
molecular
signatures
predicting
biochemical
recurrence
(BCR)
after
radical
prostatectomy
(RP).
A
comprehensive
analysis
55
features
was
conducted
using
transcriptomic
datasets
(n
=
1393),
with
further
validation
at
proteomic
level
69).
Additionally,
a
distinct
cohort
73)
underwent
urine-based
peptidomic
analysis,
culminating
urine-derived
model.
Independent
significance
assessed
Cox
proportional
hazards
modeling,
while
model's
predictive
performance
benchmarked
against
established
clinical
metrics.
An
expression
transcripts
identified
11
significantly
associated
BCR
(C-index:
0.55-0.72,
p
<
0.002).
Multivariable
models
incorporating
these
enhanced
accuracy,
surpassing
variables
0.66-0.89,
Proteomic
confirmed
five
key
collagen
proteins,
model
0.73,
95%
confidence
interval:
0.62-0.85)
demonstrated
strong
potential,
although
limited
by
small
patient
numbers.
collagen-based
predicted
overall
survival
significant
0.59-0.70,
0.01).
Collagen-based
both
urine
emerge
as
robust
biomarkers
for
following
RP.
Epigenomics,
Journal Year:
2024,
Volume and Issue:
16(11-12), P. 835 - 850
Published: June 17, 2024
Aim:
To
develop
a
methylation
marker
of
Y-chromosome
gene
in
the
early
diagnosis
prostate
cancer
(PCa).
Materials
&
methods:
We
utilized
bioinformatics
analysis
to
identify
expression
and
promoter
PRKY
PCa
other
common
malignancies.
Single-center
experiments
were
conducted
validate
diagnostic
value
PCa.
Results:
was
significantly
down-regulated
its
mechanism
may
be
related
methylation.
is
highly
specific
for
PCa,
which
superior
prostate-specific
antigen,
mpMRI
excellent
molecular
biomarkers.
Conclusion:
potential
accurate
